We quantified the risk of second cancer and late mortality in a population-based Australian cohort of 3273 adult (!15 years) allogeneic hematopoietic stem cell transplant recipients (1992 to 2007). Most recipients received nonradiation-based conditioning and a peripheral blood graft from a matched related donor. Using record linkage with death and cancer registries, 79 second cancers were identified a median of 3.5 years after transplantation. The competing-risk adjusted cumulative incidence of second cancers was 3.35% (95% CI, 2.59 to 4.24) at 10 years, and the cancer risk relative to the matched general population was 2.10 (95% CI, 1.65 to 2.56). We observed an excess risk of melanoma and lip, tongue, esophagus, and soft tissue cancers. Cancer risk relative to the general population was elevated for those transplanted for lymphoma, some leukemia subtypes, and severe aplastic anemia, recipients who developed chronic graft-versus-host disease (cGVHD) and irrespective of radiation-based conditioning or stem cell source. In those alive 2 years after transplantation (n ¼ 1463), the cumulative incidence of late mortality was 22.2% (95% CI, 19.7 to 24.9) at 10 years, and the risk of death relative to the matched general population was 13.8 (95% CI, 12.2 to 15.6). In multivariable modeling, risk of late death was reduced for females compared with males and those transplanted for chronic myeloid leukemia compared with acute myeloid leukemia; risk was increased for recipients with discordant sex donors, cGVHD, those undergoing second transplants, and disease relapse. Adults undergoing allogeneic transplantation have unique cancer and mortality risk profiles that continue to warrant prevention and surveillance activities targeted at high-risk subgroups.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is now standard of care for the treatment of certain patients with hematologic malignancies and nonmalignant disorders [1] . Patient outcomes have improved dramatically over time, but the long-recognized increased risk of second cancers [2] and late mortality [3] remains. The most common incident cancers after allogeneic HSCT are oral cavity, esophageal, and skin cancers [4] [5] [6] . Consistently observed risk factors for second cancer are pretransplant high-dose total body irradiation (TBI) and post-transplant chronic graft-versus-host disease (cGVHD) and its therapy [4, 7] . Late deaths are common and predominantly attributed to malignancy relapse, second cancers, infections, cGVHD, and organ dysfunction [8, 9] .
Several studies have quantified the risk of second cancer and late mortality after transplantation, but none has been population-based, incorporating consecutive HSCT recipients and ascertaining and standardizing the classification of outcomes from statutory registers. Studies that identify incident cancers in the cohort and the general population using identical sources, population-based cancer registries, reduce the risk of under-ascertainment and misclassification error. Furthermore, some prior studies combined allogeneic and autologous cohorts and pediatric and adult recipients, potentially masking clinically important differences among recipient subpopulations. Allogeneic transplant recipients are subject to more profound and longer-lasting immunosuppression and immune reconstitution than their autologous counterparts [10, 11] . Accurate risk estimates are required to inform allogeneic HSCT protocols and survivorship care programs [7] . Risk estimates from different countries are needed because of heterogeneity in transplanted populations, HSCT protocols, and underlying lifestyle and environmental risk factors. Therefore, we quantified the risk of second cancers (excluding nonmelanoma skin cancers) and late mortality in a retrospective population-based cohort of adult Australian allogeneic HSCT recipients from 1992 to 2007.
METHODS

Study Population
The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) records up to 99.5% of HSCTs performed in Australia since 1992 [12] . Our cohort included all adult (!15 years) allogeneic HSCT recipients recorded on the ABMTRR between 1992 and 2007, the latest date for which cancer registrations were available (n ¼ 3273).
We ascertained deaths and incident cancers by record linkage with population-based datasets: the National Death Index (1980 to 2007) and the Australian Cancer Database (1982 to 2007) . Patient name code (first 2 letters of given name and first 4 letters of surname), sex, date of birth, date of death, and state of residence were used during record linkage that was performed using an established probabilistic algorithm. A linkage probability or weight was given to each potential matching record pair and a subset of paired records underwent clerical review [13] .
The Australian Cancer Database is a register of incident primary invasive neoplasms other than basal and squamous cell carcinoma of the skin. The Australian cancer registries apply international rules when registering multiple primary cancers. Cancer incidence rates for the Australian general population were obtained from the Australian Cancer Database and recipient demographic and clinical characteristics from the ABMTRR. We received ethical approval from all relevant institutional review boards; the requirement for informed consent was waived.
Data Analysis
We excluded recipients whose malignant indication for transplantation was not identified in linkage with the Australian Cancer Database (n ¼ 174) and non-Australian residents (n ¼ 5) from the second cancer analyses. Solid cancers diagnosed at least 30 days after HSCT and hematologic malignancies diagnosed any time after HSCT were counted as second cancers. We assessed and excluded potential progressed malignant indications for transplantation. We estimated the probability of second cancer by computing the cumulative incidence, treating death from other causes as a competing risk [14] . Probabilities were calculated from the date of HSCT to the date of second cancer diagnosis, death, or censoring (December 31, 2007) .
Person-years follow-up was accrued from transplantation (or day 31) until the date of second cancer diagnosis, death, or December 31, 2007, whichever occurred first. Standardized incidence ratios, the ratio of observed and expected numbers of cancers, were computed for all cancers and for specific cancers. We calculated the expected numbers of incident cancers by multiplying the number of person-years at risk by the corresponding 5-year age-, sex-, state-and calendar yearespecific cancer incidence rates for the Australian population. All higher-order cancers were counted, and recipients did not contribute person-years at risk for their pre-HSCT cancer type.
Patients who did not link with the National Death Index but who were recorded as deceased in medical records or the ABMTRR were classified as deceased in our analyses (n ¼ 173, 10.1% of all deaths). We examined late mortality for recipients (1980 to 2005) who were alive 2 years after transplantation. Overall survival probabilities were estimated by the Kaplan-Meier method from the date of HSCT to the date of death or December 31, 2007 for those who remained alive. We computed standardized mortality ratios, the ratio of deaths observed in the study population to deaths expected in the Australian general population, for deaths from any cause. Expected deaths were calculated by multiplying the number of person-years at risk in each age, sex, state, and calendar year band by the corresponding Australian mortality rates reported by the National Death Index. Personyears at risk were computed from 2 years after the date of HSCT to the date of death or December 31, 2007. Risk factor analysis for all-cause mortality used multivariate Cox regression modeling and proportional hazards assumption testing for each covariate. Because some clinical data were missing for some patients, multiple imputation was used. Imputation allowed all patients to be included in the analyses, not just those with complete data. We imputed missing values for the following variables using chained equations [15, 16] , T cell depletion, acute GVHD, cGVHD, and donorepatient sex concordance. Variables used for imputations were age, sex, era of HSCT, donor type, donor source, relapse or persistent disease within 2 years of HSCT, and death. All analyses were performed using STATA, version 12 (StataCorp, College Station, TX).
RESULTS
The median age at HSCT was 40.4 years (range, 15.5 to 59.2), with the largest subgroup (34%) transplanted for acute myeloid leukemia (AML), a minority for nonmalignancy (4%), and very few for solid malignancy (1%; Table 1 ). At least 56% of recipients received chemotherapy only before HSCT; 7% received both chemotherapy and radiotherapy.
Most transplants were from matched related donors (66%), and similar proportions received radiation-based (TBI; 46%) and nonradiation based conditioning (45%; Table 1 ). Of those who received TBI, 51% were known to have received low-dose conditioning (single < 10 Gy or fractionated < 13 Gy). Peripheral blood was the sole source of hematopoietic stem cells for 54% of the cohort. After transplantation, 30% were known to have developed grade II or higher acute GVHD, 48% were known to have developed cGVHD, and 28% experienced relapse of their primary disease.
The median follow-up for the cohort of 3094 recipients was 2.81 person-years (interquartile range, .36 to not reached); 897 and 374 patients were alive 5 and 10 years after transplantation, respectively. The median follow-up for the 1463 recipients who survived at least 2 years was 6.74 person years (interquartile range, 3.96 to 10.5). Fifty-three percent (n ¼ 1751) of recipients died during follow-up, 85% within 2 years of transplantation.
Cancer Incidence
We observed 79 second primary cancers in 76 patients (Supplementary Table 1 ) a median of 3.54 years after HSCT (range, .13 to 13.5). Most were solid tumors (n ¼ 76, 96%) with melanoma the most common (n ¼ 19), followed by oral cavity cancers (n ¼ 15). All incident melanomas were located on the limbs (n ¼ 12) or trunk (n ¼ 7).
The cumulative incidence of all second cancers adjusting for competing risk of death was 4.44% (95% confidence interval [CI], 3.38 to 5.70): .43% (95% CI, .25 to .73) at 1 year after HSCT, 1.98% (95% CI, 1.48 to 2.59) at 5 years, and 3.35% (95% CI, 2.59 to 4.24) at 10 years ( Figure 1 ). The overall risk of cancer relative to the age-, sex-, state-, and calendar yearematched general population was modestly elevated (standardized incidence ratio, 2.10; 95% CI, 1.65 to 2.56; Table 2 ). In stratified analyses, risk was significantly elevated for all age groups and for males but not females ( Table 2) . Excess risk was observed for recipients whose indication for HSCT was AML, acute lymphoblastic leukemia, lymphoma, another leukemia subtype, or severe aplastic anemia ( Table 2) . Cancer risk was significantly increased irrespective of the source of stem cells and whether radiation-based conditioning was received but was only elevated in those known to have developed cGVHD ( Table 2 ).
The overall risk of melanoma and cancer of the tongue, lip, esophagus, and soft tissue was markedly increased relative to the general population ( Table 3 ). Risk of the common epithelial cancers, colorectal, breast, and prostate, was not elevated overall or during any post-HSCT period. The risk of any cancer was significantly elevated in the first year after transplant, 1 to 4 years from HSCT and 5 to 9 years from HSCT, but not 10 or more years from HSCT (Table 3) . Individual cancers showed different risk profiles over time from transplantation. The risk of melanoma was significantly elevated in the first year post-HSCT and 1 to 4 years from HSCT but not thereafter. Risk of lip and tongue cancer was elevated at all time periods beyond the first year from HSCT. All soft tissue sarcomas were observed within 4 years of HSCT. The risk of brain cancer, thyroid cancer, and non-Hodgkin lymphoma was increased in the first year post-HSCT on the basis of 1 to 2 incident cases, but the relative risk for the entire follow-up period was not significantly different from that for the general population. Small numbers of specific cancer types prevented meaningful within-cohort risk factor analyses.
Late Mortality (>2 Years after Transplantation)
The cumulative incidence of late death from any cause was 13.2% (95% CI, 11.5 to 15.2) at 5 years after HSCT and 22.2% (95% CI, 19.7 to 24.9) at 10 years (Table 4 ). For those disease-free 2 years after HSCT, deaths occurred gradually with increasing time since transplantation (Figure 2) . In contrast, for those with relapsed primary disease within 2 years of HSCT, most deaths occurred within 5 years of transplantation ( Figure 2) .
The risk of late death from any cause relative to the age-, sex-, state-, and calendar yearematched general population was markedly elevated (standardized mortality ratio, 13.8; 95% CI, 12.2 to 15.6; Table 5 ). Standardized mortality ratios were significantly increased for all cohort subgroups. The highest rates of late death occurred during the period 2 to 5 years after HSCT but remained elevated relative to the general population more than 10 years after HSCT.
In multivariable within-cohort risk factor analyses, risk of late death was reduced for female compared with male HSCT recipients and those transplanted for chronic myelogenous leukemia compared with AML ( Table 6 ). Risk of late death was moderately increased for recipients of discordant sex donors, those with cGVHD, and those requiring a second or higher-order HSCT and markedly increased for individuals who experienced relapse of their underlying indication for transplantation ( Table 6 ). To test the effects of our imputation on results, we performed sensitivity analyses limited to those recipients with complete records for all variables and imputed data and observed no notable differences (Supplementary Table 2 ).
DISCUSSION
Using a population-based study design, we examined second cancer and late mortality in a national cohort of adult allogeneic HSCT recipients, most of whom were treated with nonradiation-based or low-dose conditioning before receiving a peripheral blood graft from a matched related * Excluding 179 patients whose malignant indication for transplantation was not identified in linkage with the cancer registry (n ¼ 174) and non-Australian residents (n ¼ 5).
y Excluding 269 patients with unknown use of radiation in conditioning. z Excluding 141 patients with unknown stem cell source.
x Evaluated for patients followed for !100 days from HSCT; excluding 669 patients with unknown cGVHD status. donor. We observed a higher cumulative incidence of cancer at 10 years than most previous nonpopulation-based, multicenter allogeneic HSCT studies [4] [5] [6] 17] . Consistent with these studies, the excess overall risk of cancer was 2fold, and the risk of melanoma, soft tissue sarcoma, and cancers of the lip, tongue, and esophagus was markedly elevated relative to the general population. The increased risk of cancer of the oral cavity persisted throughout followup, whereas the risk of melanoma was only observed within 4 years of HSCT. The excess second cancer risk was confined to recipients who developed cGVHD but not to those who received radiation-based conditioning. We confirmed excess all-cause mortality relative to the general population among all patient subgroups, including 10-year survivors. As for prior nonpopulation-based studies, the strongest independent risk factors for late mortality in our cohort were primary disease relapse and cGVHD. Nearly 50% of our cohort experienced cGVHD, a similar proportion to that recently reported for a Center for International Blood and Marrow Transplant Research (CIBMTR) cohort of adults transplanted for leukemia or lymphoma using reduced-intensity conditioning (1995 to 2006) [18] . Our 10-year competing-riskebased cumulative cancer incidence estimate (3.35%) was identical to that cohort [18] but higher than previous estimates of 1% to 2% at 10 years from nonpopulation-based, large-scale, multicenter and national cohorts predominantly exposed to radiationbased conditioning [4] [5] [6] 17] .
We confirmed an excess risk of melanoma, soft tissue carcinoma, and cancer of the lip, tongue, and esophagus in allogeneic HSCT recipients [4] [5] [6] 18] . Overall, we did not observe a significant elevation [19] or reduction [18] in breast cancer risk or a significantly increased risk of non-Hodgkin lymphoma/post-transplant lymphoproliferative disease (PTLD) or thyroid or brain cancer [4, 5, 17] relative to the general population. However, the latter malignancies did occur at an excess risk in the first year after HSCT, as previously observed for PTLD [20] and thyroid cancer [4] . We were unable to ascertain polymorphic PTLD (International Classification of Diseases (Oncology) [ICDO-3] 9970/1), potentially the most common PTLD subtype in this setting [20] , because it was not routinely collected by cancer registries during the study period. Additionally, some HSCT-related cancer risk factors were less common in our study population than those reported in prior cohorts; specifically, T cell depletion of marrow, the strongest risk factor for PTLD, was used for only 3% (15% in CIBMTR/Fred Hutchison Cancer Research Centre [FHCRC]) [20] and TBI conditioning, associated with increased risk of nonsquamous cell malignancies, was used for only 45% (64% in CIBMTR/FHCRC) [20] . We also excluded pediatric HSCT recipients, and they exhibit the highest risk of breast, brain, and thyroid cancer in association with TBI conditioning regimens [4, 19, 21] . Finally, we had limited statistical power to examine the risk of cancers with long latency periods. Sixteen of 19 incident melanomas observed in our cohort were diagnosed within 4 years of transplantation, similar to the pattern of melanoma incidence in the largest CIBMTR cohort [4] , adult Australian autologous HSCT recipients [22] , and Australian solid organ transplant recipients [23] . Rizzo et al. [4] identified T cell depletion, TBI, and female sex as risk factors for melanoma after adult and pediatric allogeneic HSCT. In addition to these factors, it is highly likely that the underlying primary disease, in particular lymphoma, and immune dysregulation also contribute to the excess melanoma risk in our cohort [23, 24] . Interestingly, a CIBMTR analysis restricted to AML and chronic myelogenous leukemia patients treated with non-TBIebased conditioning did not observe an excess risk of melanoma [5] . As for the general population, large numbers of nevi, fair skin type, high freckle density, history of sunburn, and fair hair color [25] are likely to be contributing factors but could not be assessed in this study. Full-body skin checks before transplantation and at regular intervals thereafter with early investigation of suspicious lesions are essential elements of current clinical guidelines for survivorship care [9, 26] . In addition, patients must be counseled to use adequate sun protection and avoid excessive exposure to sunlight [9] .
The increased risk of oral cancer in allogeneic HSCT recipients has been attributed to chronic inflammation from cGVHD and exposure to high cumulative doses of immunosuppressive therapy, particularly azathioprine [4, 17, 27, 28] . In Australia, corticosteroids and calcineurin inhibitors, but rarely azathioprine, are used to treat cGVHD [29] . Our data reinforce the need for lifelong annual oral cavity examination, extending to 6-monthly in those with oral cGVHD, and counseling regarding oral hygiene and tobacco and alcohol use [9] . As for prior allogeneic HSCT cohorts [30] and an adult Australian autologous HSCT cohort over the same period [13] , we observed mortality rates higher than the matched general population that continued more than 10 years after transplantation. The potentially modifiable risk factors for late death in our cohort were disease relapse, recipientedonor sex discordance, and transplant-related toxicity in the form of cGVHD, consistent with prior cohorts [3, 8, 30] . Stem cell source did not predict late mortality, consistent with randomized trials [31, 32] and some observational studies [33] of adult allogeneic HSCT recipients. Significant efforts are underway to optimize allograft regimens, identify the determinants and mechanisms of relapse, and develop risk-adapted protocols before and after transplantation [34] [35] [36] [37] .
We minimized bias and maximized generalizability by studying an entire national cohort of adult allogeneic HSCT recipients over a 16-year period. Incident cancers were identified through linkage with population-based cancer registries, thereby maximizing ascertainment and achieving systematic classification. However, linkage was based on date of birth, sex, and transplant recipient name code rather than full name, which may have missed matching records, resulting in conservative cancer risk estimates [38] . The relatively small number of incident cancers may have contributed to some of the differences compared with prior studies; we had limited statistical power to examine the long-term second cancer risk. We also observed too few incident cancers to analyse risk factors for individual cancer types, and the wide range of incident malignancies prevented an all-cancer analysis. Detailed information on chemotherapy and radiation therapy before HSCT was not available, and although the data on HSCT therapy were comprehensive, some variables were missing for some patients. An additional limitation is the missing data on acute GVHD and cGVHD, around 25%.
In summary, the absolute risk of second cancer in adult allogeneic HSCT recipients is low, but the absolute risk of death is high. Overall, allogeneic HSCT recipients appear to have an excess relative risk of second cancer regardless of whether they receive radiation-based conditioning, whereas recipients who develop cGVHD are a consistently high-risk subgroup for both second cancer and late mortality. Although allogeneic HSCT regimens and survival rates have improved significantly over time [39] , reducing relapse and treatment-related mortality remains a priority in this patient population. Large population-based studies of wellcharacterized recipients with longitudinal data will help to further quantify risk and to better define risk-adapted protocols that include primary and secondary prevention and surveillance activities. Our study also highlights the continuing importance for patients to be counseled about their increased second cancer risk after allogeneic HSCT so they are better informed about the importance of engaging in these prevention and surveillance programs. * After multiple imputation to address missing data for T cell depletion, sex discordance, acute GVHD, and cGVHD.
y Indications were examined individually and, where the numbers of recipients was small, combined if the hazard ratios were very similar.
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